Avishai Levy is an experienced manager and a business development professional specializing in managing technology companies, translational research and deal making. Mr. Levy Joined MIGAL in August 2013. In the years before MIGAL Mr. levy focused on the development of several novel technologies and small startups as well as providing external business development services to R&D companies. Some of these activities were done under Levidel Pharmaceutical Consulting and Management. Before that, for a period of approximately six years, Mr. Levy was CEO and President of Proteologics Inc., Delaware, a US holding company and CEO of Rehovot, Israel Proteologics Ltd, a public R&D company registered in the Tel-Aviv stock exchange (TASE “PRTL”) who among its shareholders, at the time, were Teva Pharmaceutical Industries and GSK. In addition to his diverse business duties Mr. Levy is a lecturer at the Biotechnology program of the Agriculture faculty of the Hebrew University. Mr. Levy academic record include Executive LL.M studies at Northwestern law school, an M.Sc. and LL.B degrees from Tel Aviv University and BSc, Agr. from the Hebrew University of Jerusalem.